Research programme: human papillomavirus vaccine - 3SBio

Drug Profile

Research programme: human papillomavirus vaccine - 3SBio

Alternative Names: SSS 08

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator 3SBio
  • Class Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Discontinued Cervical cancer; Human papillomavirus infections

Most Recent Events

  • 16 Feb 2017 Discontinued - Preclinical for Cervical cancer (Prevention) in China (Parenteral)
  • 16 Feb 2017 Discontinued - Preclinical for Human papillomavirus infections (Prevention) in China (Parenteral)
  • 04 Dec 2007 Preclinical trials in Cervical cancer in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top